Sponsors like AstraZeneca, Merck Serono to increasingly use patient engagement in trial design for better endpoint selection, recruitment boost – experts

23 Nov 2016

Sponsors like AstraZeneca (LON:AZN) and Merck Serono, the biopharma division of Merck KGaA (ETR:MRK), are increasingly seeking patient input throughout the clinical trial process, even as early as Phase I studies, to design the most relevant endpoints and help recruit and retain trial participants, said experts. Engagement methods include running trial simulations and surveying individual patients and disease advocacy groups, they said.

The aforementioned companies have already changed trial designs in response to patient feedback, they said during a panel at Partnerships in Clinical Trials (PCT) meeting in Vienna, Austria last week.

CROs could well be involved in these offerings, although this will only complicate sponsor dilemmas about when to outsource tasks which influence public recognition and reputation, experts added.

Already a subscriber? Login to read the full article.